医学
皮质类固醇
慢性阻塞性肺病
吸入性皮质类固醇
重症监护医学
内科学
哮喘
作者
Jung-Hyun Kim,Ji‐Soo Park,Kyung-Ho Kim,Hye‐Cheol Jeong,Eun Kyung Kim,Ji‐Hyun Lee
出处
期刊:Chest
[Elsevier]
日期:2013-04-01
卷期号:143 (4): 1018-1024
被引量:64
标识
DOI:10.1378/chest.12-1225
摘要
It is well known that oral corticosteroid and anti-tumor necrosis factor-α agents increase the risk of TB. However, little is known about whether inhaled corticosteroid (ICS) increases the risk of TB. We performed this study to assess the risk of pulmonary TB among ICS users, based on the presence of the radiologic sequelae of pulmonary TB.A retrospective cohort study was performed. Between January 1, 2000, and December 31, 2005, a total of 778 patients who had COPD were recruited. Among them, 162 patients were excluded according to the exclusion criteria. In total, 616 patients were followed until December 31, 2010. They were divided into four groups according to whether they used ICS and whether they had radiologic sequelae of prior pulmonary TB.A total of 20 patients developed pulmonary TB. Kaplan-Meier estimates showed an increased risk of pulmonary TB among the ICS users who had radiologic sequelae of prior pulmonary TB ( P , .001). Multivariate Cox regression showed that ICS use was an independent risk factor for the occurrence of pulmonary TB in patients who had a normal chest radiograph (hazard ratio, 9.079; 95% CI, 1.012-81.431; P 5 .049) and in patients who had radiologic sequelae of prior pulmonary TB (hazard ratio, 24.946; 95% CI, 3.090-201.365; P 5 .003).ICS use increases the risk of pulmonary TB in patients with COPD and the risk is greater in patients who have radiologic sequelae of prior pulmonary TB.
科研通智能强力驱动
Strongly Powered by AbleSci AI